United States · FDA National Drug Code directory
VENLAFAXINE HYDROCHLORIDE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 10135-825_3d59e057-318b-f098-e063-6394a90a25be
- Product NDC
- 10135-825
- Form
- CAPSULE, EXTENDED RELEASE
- Composition / generic term
- VENLAFAXINE HYDROCHLORIDE
- Labeler
- Marlex Pharmaceuticals, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20250801
- Source listing expiry
- 20261231
Source-listed ingredients
- VENLAFAXINE HYDROCHLORIDE — 37.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-825-10) · 10135-825-10
- 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-825-30) · 10135-825-30
- 15 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-825-75) · 10135-825-75
- 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10135-825-90) · 10135-825-90
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →